Novel role of UHRF1 in the epigenetic repression of the latent HIV-1.
EGCG
Epigenetics
HIV-1 latency
Reactivation
UHRF1
Journal
EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
02
09
2021
revised:
11
03
2022
accepted:
21
03
2022
pubmed:
17
4
2022
medline:
18
5
2022
entrez:
16
4
2022
Statut:
ppublish
Résumé
The multiplicity, heterogeneity, and dynamic nature of human immunodeficiency virus type-1 (HIV-1) latency mechanisms are reflected in the current lack of functional cure for HIV-1. Accordingly, all classes of latency-reversing agents (LRAs) have been reported to present variable ex vivo potencies. Here, we investigated the molecular mechanisms underlying the potency variability of one LRA: the DNA methylation inhibitor 5-aza-2'-deoxycytidine (5-AzadC). We employed epigenetic interrogation methods (electrophoretic mobility shift assays, chromatin immunoprecipitation, Infinium array) in complementary HIV-1 infection models (latently-infected T-cell line models, primary CD4 We uncovered specific demethylation CpG signatures induced by 5-AzadC in the HIV-1 promoter. By analyzing the binding modalities to these CpG, we revealed the recruitment of the epigenetic integrator Ubiquitin-like with PHD and RING finger domain 1 (UHRF1) to the HIV-1 promoter. We showed that UHRF1 redundantly binds to the HIV-1 promoter with different binding modalities where DNA methylation was either non-essential, essential or enhancing UHRF1 binding. We further demonstrated the role of UHRF1 in the epigenetic repression of the latent viral promoter by a concerted control of DNA and histone methylations. A better understanding of the molecular mechanisms of HIV-1 latency allows for the development of innovative antiviral strategies. As a proof-of-concept, we showed that pharmacological inhibition of UHRF1 in ex vivo HIV Funding was provided by the Belgian National Fund for Scientific Research (F.R.S.-FNRS, Belgium), the « Fondation Roi Baudouin », the NEAT (European AIDS Treatment Network) program, the Internationale Brachet Stiftung, ViiV Healthcare, the Télévie, the Walloon Region (« Fonds de Maturation »), « Les Amis des Instituts Pasteur à Bruxelles, asbl », the University of Brussels (Action de Recherche Concertée ULB grant), the Marie Skodowska Curie COFUND action, the European Union's Horizon 2020 research and innovation program under grant agreement No 691119-EU4HIVCURE-H2020-MSCA-RISE-2015, the French Agency for Research on AIDS and Viral Hepatitis (ANRS), the Sidaction and the "Alsace contre le Cancer" Foundation. This work is supported by 1UM1AI164562-01, co-funded by National Heart, Lung and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, National Institute on Drug Abuse and the National Institute of Allergy and Infectious Diseases.
Sections du résumé
BACKGROUND
BACKGROUND
The multiplicity, heterogeneity, and dynamic nature of human immunodeficiency virus type-1 (HIV-1) latency mechanisms are reflected in the current lack of functional cure for HIV-1. Accordingly, all classes of latency-reversing agents (LRAs) have been reported to present variable ex vivo potencies. Here, we investigated the molecular mechanisms underlying the potency variability of one LRA: the DNA methylation inhibitor 5-aza-2'-deoxycytidine (5-AzadC).
METHODS
METHODS
We employed epigenetic interrogation methods (electrophoretic mobility shift assays, chromatin immunoprecipitation, Infinium array) in complementary HIV-1 infection models (latently-infected T-cell line models, primary CD4
FINDINGS
RESULTS
We uncovered specific demethylation CpG signatures induced by 5-AzadC in the HIV-1 promoter. By analyzing the binding modalities to these CpG, we revealed the recruitment of the epigenetic integrator Ubiquitin-like with PHD and RING finger domain 1 (UHRF1) to the HIV-1 promoter. We showed that UHRF1 redundantly binds to the HIV-1 promoter with different binding modalities where DNA methylation was either non-essential, essential or enhancing UHRF1 binding. We further demonstrated the role of UHRF1 in the epigenetic repression of the latent viral promoter by a concerted control of DNA and histone methylations.
INTERPRETATION
CONCLUSIONS
A better understanding of the molecular mechanisms of HIV-1 latency allows for the development of innovative antiviral strategies. As a proof-of-concept, we showed that pharmacological inhibition of UHRF1 in ex vivo HIV
FUNDING
BACKGROUND
Funding was provided by the Belgian National Fund for Scientific Research (F.R.S.-FNRS, Belgium), the « Fondation Roi Baudouin », the NEAT (European AIDS Treatment Network) program, the Internationale Brachet Stiftung, ViiV Healthcare, the Télévie, the Walloon Region (« Fonds de Maturation »), « Les Amis des Instituts Pasteur à Bruxelles, asbl », the University of Brussels (Action de Recherche Concertée ULB grant), the Marie Skodowska Curie COFUND action, the European Union's Horizon 2020 research and innovation program under grant agreement No 691119-EU4HIVCURE-H2020-MSCA-RISE-2015, the French Agency for Research on AIDS and Viral Hepatitis (ANRS), the Sidaction and the "Alsace contre le Cancer" Foundation. This work is supported by 1UM1AI164562-01, co-funded by National Heart, Lung and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, National Institute on Drug Abuse and the National Institute of Allergy and Infectious Diseases.
Identifiants
pubmed: 35429693
pii: S2352-3964(22)00169-4
doi: 10.1016/j.ebiom.2022.103985
pmc: PMC9038550
pii:
doi:
Substances chimiques
CCAAT-Enhancer-Binding Proteins
0
Decitabine
776B62CQ27
UHRF1 protein, human
EC 2.3.2.27
Ubiquitin-Protein Ligases
EC 2.3.2.27
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
103985Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors declare no conflicts of interest.
Références
Retrovirology. 2009 Dec 04;6:111
pubmed: 19961595
J Biol Chem. 2014 Feb 14;289(7):4106-15
pubmed: 24368767
EMBO J. 2003 Apr 15;22(8):1868-77
pubmed: 12682019
PLoS One. 2014 Feb 14;9(2):e88116
pubmed: 24551078
Biochem Biophys Res Commun. 2013 Jan 4;430(1):208-12
pubmed: 23201574
PLoS One. 2011 Apr 19;6(4):e19084
pubmed: 21526160
PLoS One. 2011;6(10):e25884
pubmed: 21991380
Cell Res. 2015 Aug;25(8):911-29
pubmed: 26065575
PLoS One. 2011 Mar 07;6(3):e17388
pubmed: 21408221
AIDS. 2003 Jan 24;17(2):167-75
pubmed: 12545075
Cell Host Microbe. 2013 Jun 12;13(6):665-77
pubmed: 23768491
Semin Immunopathol. 2020 Apr;42(2):187-200
pubmed: 32047948
Virus Res. 2021 Feb;293:198260
pubmed: 33316352
J Biol Chem. 2010 Jun 18;285(25):19434-49
pubmed: 20413592
EMBO J. 2007 Jan 24;26(2):412-23
pubmed: 17245431
Sci Rep. 2021 Jan 29;11(1):2692
pubmed: 33514850
Oncogene. 2004 Oct 7;23(46):7601-10
pubmed: 15361834
Epigenetics. 2009 Jan;4(1):8-14
pubmed: 19077538
Nature. 2007 Dec 6;450(7171):908-12
pubmed: 17994007
PLoS Pathog. 2015 Jul 30;11(7):e1005063
pubmed: 26225566
mBio. 2021 Aug 31;12(4):e0162521
pubmed: 34465029
Nat Commun. 2019 Oct 17;10(1):4705
pubmed: 31624244
Genes (Basel). 2018 Dec 03;9(12):
pubmed: 30513966
Brief Bioinform. 2014 Nov;15(6):929-41
pubmed: 23990268
Nucleic Acids Res. 2000 Feb 1;28(3):663-8
pubmed: 10637316
Annu Rev Virol. 2021 Sep 29;8(1):491-514
pubmed: 34586875
Biophys Chem. 2013 Jan;171:38-45
pubmed: 23245651
Front Microbiol. 2020 Jan 24;10:3060
pubmed: 32038533
Science. 2010 Jul 9;329(5988):174-80
pubmed: 20616270
Nucleic Acids Res. 1983 Mar 11;11(5):1475-89
pubmed: 6828386
Elife. 2018 May 01;7:
pubmed: 29714165
Epigenomics. 2016 Mar;8(3):389-99
pubmed: 26673039
PLoS Pathog. 2009 Jun;5(6):e1000495
pubmed: 19557157
AIDS. 2012 Jun 19;26(10):1261-8
pubmed: 22472858
Antiviral Res. 2002 Jan;53(1):19-34
pubmed: 11684313
J Virol. 2012 May;86(9):5390-2
pubmed: 22345448
Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4459-64
pubmed: 15753290
Mol Cell Biol. 2003 Sep;23(17):6200-9
pubmed: 12917341
PLoS Pathog. 2019 Jan 15;15(1):e1007498
pubmed: 30645648
Cell Stem Cell. 2016 Jul 7;19(1):81-94
pubmed: 27151458
J Allergy Clin Immunol. 2006 Dec;118(6):1369-74
pubmed: 17157668
PLoS Pathog. 2021 Oct 21;17(10):e1010014
pubmed: 34673825
J Virol. 2012 Dec;86(23):13081-4
pubmed: 22973038
Mol Cell. 2016 Apr 21;62(2):157-168
pubmed: 27105112
Oncotarget. 2018 May 25;9(40):26243-26258
pubmed: 29899856
Nat Struct Mol Biol. 2021 Jul;28(7):594-603
pubmed: 34140676
Gene Ther. 2019 Feb;26(1-2):29-39
pubmed: 30443044
EBioMedicine. 2020 Aug;58:102906
pubmed: 32707449
Curr Opin Virol. 2019 Oct;38:63-69
pubmed: 31509794
Science. 1996 Apr 12;272(5259):263-7
pubmed: 8602510
J Clin Microbiol. 2008 Jul;46(7):2206-11
pubmed: 18463204
Nucleic Acids Res. 2009 Feb;37(2):493-505
pubmed: 19056828
Biochem Pharmacol. 2011 Dec 15;82(12):1807-21
pubmed: 21827739
J Virol. 2002 Nov;76(21):11091-103
pubmed: 12368351
Clin Epigenetics. 2016 Feb 19;8:19
pubmed: 26900410
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Annu Rev Med. 2018 Jan 29;69:421-436
pubmed: 29099677
Mol Cell. 2018 Nov 15;72(4):753-765.e6
pubmed: 30392931
Viruses. 2021 Apr 29;13(5):
pubmed: 33946976
EMBO Mol Med. 2015 Dec 17;8(2):117-38
pubmed: 26681773
Cell. 2013 Oct 24;155(3):540-51
pubmed: 24243014
PLoS Pathog. 2013;9(12):e1003834
pubmed: 24385908
Nucleic Acids Res. 2000 Mar 1;28(5):1053-8
pubmed: 10666443
J Clin Microbiol. 1990 Mar;28(3):495-503
pubmed: 1691208
J Virol. 2001 Feb;75(4):1842-56
pubmed: 11160683
PLoS Pathog. 2009 Aug;5(8):e1000554
pubmed: 19696893
J Virol. 1997 Aug;71(8):6113-27
pubmed: 9223506
Prog Mol Biol Transl Sci. 2011;101:377-98
pubmed: 21507359
Epigenomics. 2011 Dec;3(6):771-84
pubmed: 22126295
J Immunol. 2009 Nov 15;183(10):6513-21
pubmed: 19841192
Clin Epigenetics. 2019 Sep 13;11(1):134
pubmed: 31519219
EMBO Rep. 2009 Nov;10(11):1259-64
pubmed: 19798101
Trends Immunol. 2017 Mar;38(3):217-228
pubmed: 28073694
Cell. 2022 Jan 20;185(2):266-282.e15
pubmed: 35026153
Semin Immunol. 2021 Jan;51:101478
pubmed: 33972164
EMBO Rep. 2020 Nov 5;21(11):e49305
pubmed: 32924251
Methods. 2011 Jan;53(1):47-53
pubmed: 20670606
Nat Protoc. 2008;3(7):1240-8
pubmed: 18600229
Virology. 2017 Jun;506:34-44
pubmed: 28340355
Eur J Med Chem. 2016 May 23;114:390-6
pubmed: 27049577
J Acquir Immune Defic Syndr. 2019 Apr 15;80(5):605-613
pubmed: 30768485
J Med Virol. 2009 Feb;81(2):217-23
pubmed: 19107966
Science. 1986 May 9;232(4751):755-9
pubmed: 3008338
PLoS One. 2009 Dec 31;4(12):e8490
pubmed: 20046870
Virology. 2014 Jan 20;449:181-9
pubmed: 24418551
Science. 2007 Sep 21;317(5845):1760-4
pubmed: 17673620
Nat Rev Immunol. 2012 Jul 20;12(8):607-14
pubmed: 22814509
Retrovirology. 2013 Oct 24;10:120
pubmed: 24156270
Oncotarget. 2017 Apr 24;8(31):51946-51962
pubmed: 28881702
Cancer Res. 2000 Jan 1;60(1):121-8
pubmed: 10646863
Vaccines (Basel). 2021 May 17;9(5):
pubmed: 34067608